[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353543-105":59,"doc-detail-353543-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-circulating-proteome-and-cancer-risk-a-systematic-literature-review-and-meta-analysis-of-26-prospective-studies-with-genetic-validation","The circulating proteome and cancer risk - a systematic literature review and meta-analysis of 26 prospective studies with genetic validation","","Proteins play a central role in cancer aetiology and also shape cancer detection, treatment, and prognosis. Evidence from prospective proteomic studies for circulating risk markers has expanded quickly, yet the overall landscape remains unclear. A systematic review and meta-analysis synthesised multiplex prospective cohort data and applied reference screening, with genetic validation using Mendelian randomisation and exome-protein-score approaches. Results integrated 26 studies, identifying protein–cancer associations and highlighting evidence gaps across multiple cancer sites.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-circulating-proteome-and-cancer-risk-a-systematic-literature-review-and-meta-analysis-of-26-prospective-studies-with-genetic-validation/353543/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-circulating-proteome-and-cancer-risk-a-systematic-literature-review-and-meta-analysis-of-26-prospective-studies-with-genetic-validation/353543.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the review address about circulating proteins and cancer risk?","Question",{"text":112,"@type":113},"It synthesises whether circulating proteins measured in prospective proteomic studies are associated with risk of incident cancer across multiple cancer sites, and clarifies where evidence is consistent or uncertain.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were eligible studies selected and what analytical approach was used?",{"text":117,"@type":113},"Prospective cohort studies using multiplex protein panels, enrolling adults without baseline cancer diagnosis, and reporting associations with incident cancer were included. The review combined systematic searching with reference screening and meta-analyses, followed by genetic validation using approaches such as Mendelian randomisation and exome-protein-score analyses.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main findings regarding protein–cancer associations across cancer sites?",{"text":121,"@type":113},"Across 26 unique studies, the review detected 216 protein–cancer associations passing false-discovery-rate correction, with 131 significant only after meta-analysis. Significant associations were reported for stomach, colorectal, lung, breast, and prostate cancers, while bladder showed no significant associations, and meta-analyses were not possible for oesophageal, liver, cervical, or thyroid cancers due to limited data.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353543,1790450551,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","Articles  \nThe circulating proteome and cancer risk: a systematic literature review and meta-analysis of 26 prospective studies with genetic validation  \nAlison Dillman,a HaigeAn,a Zhe Huang,a Wing Ching Chan,a Sarah Blagden,b Mahboubeh Parsaeian,a Joshua R. Atkins,a Karl Smith-Byrne,a,∗,c and Ruth C. Travisa,c  \naCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK bDepartment of Oncology, University of Oxford, Oxford, UK  \nSummary  \nBackground Proteins have an integral role in cancer aetiology and inform cancer detection, treatment, and prognosis. While published data from prospective proteomic studies identifying early detection cancer risk markers have rapidly increased in the past five years, the landscape of evidence remains unclear. We aim to synthesise the evidence on circulating proteins and cancer risk.  \nMethods We conducted a systematic review and meta-analysis. We searched Embase and Medline up to December 2023 with reference-list screening and hand-searching up to August 2025. Prospective cohort studies were eligible if they used multiplex panels, included adults without cancer diagnosis at baseline, and reported associations between baseline circulating proteins and risk of incident cancer. Based on highest global incidence, we includedoesophageal, stomach, colorectal, liver, lung, breast, cervical, prostate, bladder, thyroid cancer. We conducted exome-protein-score and Mendelian-randomisation analyses and integrated exome-gene-burden results for protein associations that passed false-discovery-rate correction to assess protein roles in cancer aetiology.  \nFindings Of 4949 articles, we included 26 unique studies comprising 84,129 participants and 14,326 cases. The studies profiled 2434 unique proteins and reported 19,130 total protein-cancer-associations. We conducted 3448 meta-analyses and detected 216 associations (131 significant only in the meta-analyses) that passed falsediscovery-rate correction for stomach (n = 2), colorectal (n = 27), lung (n = 172), breast (n = 14), and prostate (n = 1) cancer. No significant associations were observed for bladder cancer. Meta-analyses were not possible for oesophageal, liver, cervical, or thyroid cancer, due to limited data. Supporting genetic evidence was found for 39 protein-cancer-associations.  \nInterpretation We identified 131 protein-cancer-associations that reached statistical significance in the meta-analysis, of which some may be cancer markers and others may have aetiological roles, indicated by supporting genetic analyses, including ITGA11 and lung cancer. Our findings highlight the need for large, diverse, and mature prospective proteomic cohort studies of cancer risk to ensure the equity and generalisability of insights into cancer risk.  \nFunding AD is funded by the University of Oxford. KSB is funded by Cancer Research UK and UK Research Institute. RCT is funded by Cancer Research UK. The funders had no role in study design, data collection, analysis, decision to publish, or manuscript preparation.  \nCopyright © 2025 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-nd/4.0/](creativecommons.org/licenses/by-nc-nd/4.0/)).  \nKeywords: Systematic review; Meta-analysis; Proteomics; Cancer; Exome; Mendelian randomisation  \n*Corresponding author. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford, OX3 7LF, UK.  \nE-mail [address:](address: karl.smith-byrne@ndph.ox.ac.uk)[ karl.smith-byrne@ndph.ox.ac.uk](address: karl.smith-byrne@ndph.ox.ac.uk) (K. Smith-Byrne).  \ncKarl Smith-Byrne and Ruth C Travis contributed equally.  \neBioMedicine 2026;124: 106117  \nPublished Online xxx [https://doi.org/10](https://doi.org/10) . 1016/j.ebiom.2025 . 106117  \n[www.thelancet.com Vol](www.thelancet.com Vol) 124 February, 2026 1  \nArticles  \nRese","cbCaibKa81O8Ri1Z","https://ap.wps.com/l/cbCaibKa81O8Ri1Z","pdf",2541764,17,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n# Research in context\n## Evidence before this study\n## Added value of this study\n## Implications of all the available evidence","[{\"question\":\"What question does the review address about circulating proteins and cancer risk?\",\"answer\":\"It synthesises whether circulating proteins measured in prospective proteomic studies are associated with risk of incident cancer across multiple cancer sites, and clarifies where evidence is consistent or uncertain.\"},{\"question\":\"How were eligible studies selected and what analytical approach was used?\",\"answer\":\"Prospective cohort studies using multiplex protein panels, enrolling adults without baseline cancer diagnosis, and reporting associations with incident cancer were included. The review combined systematic searching with reference screening and meta-analyses, followed by genetic validation using approaches such as Mendelian randomisation and exome-protein-score analyses.\"},{\"question\":\"What were the main findings regarding protein–cancer associations across cancer sites?\",\"answer\":\"Across 26 unique studies, the review detected 216 protein–cancer associations passing false-discovery-rate correction, with 131 significant only after meta-analysis. Significant associations were reported for stomach, colorectal, lung, breast, and prostate cancers, while bladder showed no significant associations, and meta-analyses were not possible for oesophageal, liver, cervical, or thyroid cancers due to limited data.\"}]","The circulating proteome and cancer risk - a systematic literature review and meta-analysis of 26 prospective studies with genetic validation | PDF",1790105976,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ae28b0c5936551fd31ce3cc22c6a9c7.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d913eb5c7c9c878574136e252b3bc24e.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/601c868bf4db685a1a0849dd89fe48db.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6404ae8816eab0c396f0ce04a903f02.webp",980,1306]